The MarketWatch News Department was not involved in the creation of this content. Vyome's offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 ...
Enphase Energy (ENPH) may be undervalued despite near-term headwinds—see key catalysts, new products, and why a rebound could ...
Hosted on MSN
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations
The company expects top line data from the PIK3CA mutant cohort of the VIKTORIA-1 trial in late Q1 or Q2 2026. Sullivan stated, "We expect to complete the submission [to FDA] this quarter." The ...
Management reaffirmed confidence in scaling strategy and future revenue growth, with Bednar stating, "We remain confident in our scaling strategy and believe these investments will drive significant ...
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity Vyome’s offering is a first-of-its-kind in a broader $20B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback